# Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients

> **NCT01155778** · PHASE1,PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 12 (actual)

## Conditions studied

- Mucopolysaccharidosis (MPS)

## Interventions

- **BIOLOGICAL:** Recombinant human heparan N-sulfatase (rhHNS)

## Key facts

- **NCT ID:** NCT01155778
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-01
- **Primary completion:** 2012-09-01
- **Final completion:** 2012-09-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01155778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01155778, "Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01155778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*